Amivantamab‑chemotherapy shows longest overall survival for EGFR exon 20 insertion NSCLC in phase 3 trial

The phase 3 PAPILLON study has reported that first‑line treatment with amivantamab combined with carboplatin‑pemetrexed (amivantamab‑chemotherapy) was associated with a numerically longer overall survival compared with standard chemotherapy alone in patients with previously untreated advanced non‑small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion (Ex20ins) mutations. The data were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

In the randomized trial, patients receiving the amivantamab‑chemotherapy regimen demonstrated improved survival outcomes relative to those receiving chemotherapy alone, suggesting that the addition of the bispecific antibody amivantamab may provide clinical benefit for this molecularly defined subgroup of NSCLC. The study’s findings contribute to the growing evidence base for targeted therapies in Ex20ins NSCLC and may influence future treatment guidelines.

If confirmed in further analyses, these results could support the use of amivantamab in combination with platinum‑based chemotherapy as a new first‑line option for patients with advanced EGFR exon 20 insertion NSCLC, potentially extending survival beyond what is achieved with conventional chemotherapy.